Business context and reporting period
The filing is Proteon Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, not a filing for Protara Therapeutics. The company was a development-stage biopharmaceutical business focused primarily on PRT-201, an investigational treatment intended to reduce vascular-access failure in patients undergoing hemodialysis. It had no product sales or approved products.
In 2014, Proteon began its first Phase 3 trial of PRT-201 for radiocephalic arteriovenous fistulas (AVFs). The company completed an IPO in October and converted its preferred stock to common stock.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $2.948 million | None |
| Research and development | $6.432 million | $3.994 million |
| General and administrative | $4.096 million | $3.128 million |
| Operating loss | $7.580 million | $7.122 million |
| Net loss | $3.342 million | $7.912 million |
| Net loss attributable to common stockholders | $9.695 million | $14.031 million |
| Operating cash flow | $(9.990) million | $(6.657) million |
2014 revenue was a one-time $2.948 million recognition of deferred revenue after residual rights under a 2009 agreement expired; it was not product revenue. Annual net loss narrowed, in part because of $5.071 million in other income, primarily from a fair-value change in Series D investor rights. Research and development spending rose as Phase 3 work advanced. Profit margins are not meaningful for this pre-commercial company.
At year-end, cash and cash equivalents were $68.840 million and available-for-sale investments were $14.755 million, totaling $83.595 million. Working capital was $82.263 million. Total liabilities were $2.338 million; convertible notes had been converted into preferred stock, and no debt was reported at year-end. The company reported $88.520 million of financing cash inflow, chiefly from the Series D financing and IPO.
In fourth-quarter 2014, the company reported net income of $7.233 million and diluted earnings per share of $0.48, despite no revenue that quarter. The filing attributes material annual other income mainly to a non-cash fair-value change; quarterly results therefore warrant review for the timing and composition of unusual items.
Material changes versus the prior period
- Revenue rose from zero in 2013 due to the one-time deferred-revenue recognition; it does not indicate recurring sales.
- Operating expenses increased by $3.406 million, including higher Phase 3 research and development costs and public-company expenses.
- Operating cash use increased by $3.333 million.
- Liquidity increased substantially following the $62.5 million net IPO proceeds and approximately $24.5 million net Series D proceeds. Preferred shares converted to common stock at the IPO.
Outlook, risks and unusual items
Management estimated existing cash and investments would fund operations into 2018, supporting the first Phase 3 readout, the start of the second Phase 3 trial and CMC activities. It also stated that available resources were not expected to fund completion of the second Phase 3 trial, so additional financing or a partnership would likely be needed. The first trial’s results were expected in the first quarter of 2017; the second trial was expected to begin in the second quarter of 2015.
The Phase 2 primary endpoint did not reach statistical significance in the overall population. Favorable findings in radiocephalic AVFs and analyses excluding central-stenosis events were non-prespecified, so their reliability and ability to predict Phase 3 outcomes are uncertain. Other principal risks include trial enrollment, regulatory approval, reliance on contract manufacturers and CROs, reimbursement and commercialization execution, and dependence on additional capital. The filing disclosed that finished-product supplier Jubilant HollisterStier had received an FDA cGMP Warning Letter in 2013; the FDA told Proteon in February 2014 that it did not affect the batch intended for Phase 3.
Management reported effective disclosure controls as of year-end. The auditors issued an unqualified opinion on the financial statements but did not audit internal control over financial reporting. No material legal proceeding was reported. Proteon had 11 full-time and one part-time employee as of March 2015 and had not established a sales organization.
Important facts for investors to verify
- Confirm the registrant identity: the supplied 10-K is for Proteon Therapeutics, not Protara Therapeutics.
- Review the detailed financial statements and notes to reconcile fourth-quarter net income with the full-year loss and assess the non-cash fair-value items.
- Track Phase 3 enrollment, protocol execution, endpoint results and whether FDA will require both pivotal trials.
- Assess the timing, terms and dilution risk of financing needed to complete the second Phase 3 trial and fund later development.
- Monitor manufacturing readiness, supplier compliance, CMC validation and any dependence on single-source suppliers.